Compare DNLI & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNLI | OGN |
|---|---|---|
| Founded | 2013 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2017 | 2020 |
| Metric | DNLI | OGN |
|---|---|---|
| Price | $18.63 | $13.76 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 20 | 5 |
| Target Price | ★ $35.75 | $11.25 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 0.58% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.95 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $158.26 | $2.51 |
| P/E Ratio | ★ N/A | $14.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.75 | $5.69 |
| 52 Week High | $27.30 | $13.83 |
| Indicator | DNLI | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.65 | 53.95 |
| Support Level | $18.07 | $13.46 |
| Resistance Level | $20.84 | $13.77 |
| Average True Range (ATR) | 0.82 | 0.04 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 47.64 | 42.31 |
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.